Emmaus Life Sciences, INC 10-Q quarterly reports

Emmaus Life Sciences, Inc. reported a significant revenue increase in Q2 2026 driven by its licensing agreement with NeoImmuneTech, Inc., though the company continues to face substantial going concern uncertainties.

Emmaus Life Sciences reports a Q1 2026 net loss of $3.3 million amid ongoing liquidity challenges and a transition to a new distribution model for Endari.

Emmaus Life Sciences reported a significant revenue drop and increased net loss for Q3 2025, raising substantial doubt about its ability to continue as a going concern amidst generic competition.

Emmaus Life Sciences reported a significant revenue decline and continued financial distress in its latest quarterly filing, citing generic competition as a primary factor.

Emmaus Life Sciences experienced a slight decrease in net revenues for Q1 2025, primarily due to increased competition from a generic version of their sickle cell disease treatment, Endari, in the U.S. market.

Emmaus Life Sciences experienced a revenue increase in Q3 2024 compared to Q3 2023, but faces challenges due to the expiration of Endari's exclusivity and the entry of generic competition.

Emmaus Life Sciences experienced a significant decrease in revenue for the second quarter of 2024 due to supply chain disruptions and the launch of a generic competitor, while also reporting a net loss.

Emmaus Life Sciences experienced a significant revenue decrease in Q1 2024 due to supply chain disruptions and faces new challenges with the launch of a generic competitor.